Aptevo raises ~$2.75M gross in registered direct offering at $0.515/share

Aptevo Therapeutics Inc.

Offering of 5,339,806 shares (or pre-funded warrants) and 10,679,612 common warrants at $0.515/share; net proceeds ~$2.3M.
Common warrants exercisable at $0.515/share upon stockholder approval, expire 5 years later.
Existing warrants from Aug 2023, Nov 2023, Apr 2024 amended to $0.515 exercise price, also subject to stockholder approval.
Proceeds for clinical development of product candidates and working capital.
Roth Capital Partners placement agent; closing July 1, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.